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Abstract 30 
Background 31 
 32 
Enteral feeding will induce remission in as many as 80-90% of compliant patients with active Crohn’s 33 
Disease (CD) but its method of action remains uncertain.  This study was designed to examine its effects 34 
on the colonic microbiome.  35 
 36 
Method 37 
 38 
Healthy volunteers and patients with CD followed a regimen confined to enteral feeds alone for one or 39 
two weeks respectively. Chemicals excreted on breath or in faeces were characterised at the start and at 40 
the end of the feeding period by gas chromatography mass spectrometry (GC/MS). 41 
 42 
Results 43 
One week of feeding in healthy volunteers caused significant changes in stool colour and deterioration in 44 
breath odour, together with increased excretion of phenol and indoles on the breath.  Feeding for two 45 
weeks in patients with CD produced significant improvements in symptoms and a decrease in the 46 
concentration of C-reactive protein. The faecal concentrations of microbial products including short chain 47 
fatty acids (SCFAs), and potentially toxic substances including 1-propanol,  1-butanol and the methyl and 48 
ethyl esters of SCFAs showed significant falls.   49 
 50 
Conclusion 51 
A significant change occurs in the production of microbial metabolites after enteral feeding in both 52 
healthy volunteers and patients with CD.  Many of those detected in CD are toxic and may feasibly lead 53 
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to the immunological attack on the gut microbiota, which is characteristic of IBD.  The reduction in the 54 
production of such metabolites after enteral feeding may be the reason for its effectiveness in CD. 55 
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Introduction 80 
Despite the increasing frequency of Crohn’s disease, its treatment remains unsatisfactory.  Many of the 81 
therapeutic agents used have unpleasant or even dangerous side effects and some are very expensive.  The 82 
continuing perception of CD as a relapsing and remitting disorder emphasises the difficulty in 83 
maintaining long term control.  A complete cure remains elusive.  84 
 85 
Reports of a positive response to dietary manipulation in CD have emerged from several sources.1-8   2-4 86 
weeks of total enteral feeding has been reported to reduce remission in 85-90% of compliant patients 87 
suffering active CD. 1-6.  Lack of understanding of the method of action of enteral feeds in CD has 88 
however, discouraged their use. 2-8   89 
 90 
Enteral feeds are nutritionally complete liquid mixtures of pre-digested foods presenting nitrogen as 91 
amino acids, oligopeptides or a single protein, carbohydrates as simple sugars, typically malto-dextrins, 92 
and fat as a single oil, (eg. Rapeseed oil), together with minerals and vitamins. They are nutritionally 93 
complete.  94 
 95 
Suggestions as to the method of action of enteral feeding are many, but it is now known that bowel rest  7 96 
and the reduction of potential food allergens 2-4   are incorrect.  Enteral feeding is unlikely to have 97 
therapeutic benefit by producing immunosuppression as it is ineffective in the treatment of ulcerative 98 
colitis. 3    Reduction in inflammation can be detected before any improvement in nutritional state begins, 8   99 
and the suggestion that dietary particles might be important was not supported by a controlled trial. 9   100 
 101 
The increasing evidence that inflammation in CD is provoked by an immune response targeted against the 102 
intestinal microbiome implies that manipulation of the metabolic activity of the microbiota might have a 103 
role in the treatment of this disease 10,12 We and others have recently demonstrated an association between 104 
Crohn’s disease and the profile volatile organic compounds obtained from breath and faecal headspace 105 
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samples 16,34. These measurements are a useful indication of changes in the gut microbiome, being simple, 106 
rapid and non-invasive. We have used this approach here in a study of the effects of enteral feeding.  It 107 
has been suggested that food intolerance, as distinct from food allergy, might reflect an interaction 108 
between unabsorbed food residues and the intestinal microbiome.13      As the nutrients contained in enteral 109 
feeds are absorbed high in the small intestine, they supply little in the way of energy substrates to micro-110 
organisms in the lower bowel. This might lead to changes in microbial metabolism which in turn could 111 
lead to a reduction in inflammation.   The present studies were designed to investigate this possibility. 112 
 113 
Methods 114 
Study 1  Healthy volunteers 115 
Volunteers were recruited from students of either sex aged 18-65 years, at Cranfield University who were 116 
in good health and eating a normal diet. A total of 12 subjects was recruited aged 23-32, of which 8 were 117 
female. Subjects suffering conditions possibly requiring specific diets e.g. irritable bowel syndrome 118 
(IBS), or coeliac disease were excluded.  Other exclusions were pregnancy or lactation, a course of 119 
antibiotics in the previous six weeks, bacterial products such as pro- or pre- biotics and any chronic 120 
medication other than oral contraceptives. 121 
 122 
Subjects were randomly allocated to take either E028 extra (Nutricia UK Liverpool), or Modulen-IBD 123 
(Nestle Ltd, Croydon UK), for 7 days with all other foodstuffs excluded except water ad libitum..  124 
Nutritional requirements were calculated for each individual using Schofield’s equation. 14    125 
After 7 days subjects returned to normal diets for 21 days before commencing the alternative enteral feed 126 
for a further 7 days.  The two feeds were administered 4 weeks apart in order that they were taken at the 127 
same stage of the menstrual cycles of female volunteers. During enteral feeding, subjects were asked to 128 
record how much feed they consumed and to complete symptom score sheets recording on a daily basis 129 
stool frequency, consistency and colour and any changes in breath odour.  Weights were recorded and 130 
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breath samples taken before the study and after each week of enteral feeding.  This trial was an open, 131 
randomised controlled study performed at Cranfield University and approved by the ethics committee of 132 
Cranfield University and the NHS Cambridge local research ethics committee. 133 
Volunteers were provided with a sheet depicting a range of faecal colours ranging from dark brown to 134 
bright green (copies supplied to the editor) and asked to assess the stool colour, consistency and 135 
frequency.  They were asked to record daily changes in breath odour which was assessed subjectively on 136 
a scale from 1 (odourless) to 4 (extremely unpleasant). 137 
Bio-VOC samplers were used according to manufacturer’s recommendations to obtain a one-litre end-138 
tidal breath sample after breakfast on the first day of each feeding period. Samples were injected onto 139 
Thermal desorption tubes containing 1:1 Tenax TA and Carbotrap adsorbents (Markes International, 140 
Llantrisant, UK). 141 
Study 2  Patients with Crohn’s disease 142 
Patients aged 18-65 years were recruited in the department of Gastroenterology, Addenbrooke’s Hospital, 143 
Cambridge. A total of 17 patients each provided a faecal sample before treatment with enteral feed 144 
E028extra  and again when they went into remission. At recruitment, all had symptoms of active disease.   145 
The diagnosis of CD was made by standard diagnostic criteria and the severity of symptoms was assessed 146 
using the Harvey and Bradshaw Index15.  The concentration of C-reactive protein (CRP) in serum 147 
samples obtained at each visit was determined by the Biochemistry Department of Addenbrooke’s 148 
Hospital to provide an objective measure of disease activity.   149 
 150 
Any patients who had received antibiotics in the previous 6 weeks were excluded.  Some were taking 151 
medication including 5-aminosalicylic acid compounds and/or azathioprine which had been insufficient 152 
to control their symptoms, but none had received previous dietary treatment. They were asked to continue 153 
such medication during the period of feeding with elemental diet. Non-fasting morning samples of faeces 154 
were obtained before starting two weeks treatment with E028 extra (Nutricia Liverpool UK) with 155 
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amounts again being calculated by Schofield’s equation.  A further faecal sample was obtained at the end 156 
of this period.  Samples were delivered to the hospital on the same day as passed with a maximum delay 157 
before freezing of 4 hours.  They were stored at -40°C until transferred to the laboratory for analysis. 158 
Ethical permission for this study was granted by the Leeds West LREC (Ref: 07/Q1205/39). 159 
Laboratory analysis   160 
An internal standard solution comprising 50 ng deuterated (D8) toluene (Supelco Cat no 48,593) in 161 
methanol was added to each tube according to the manufacturer’s instructions (Markes International Ltd, 162 
Llantrisant,UK). Head space samples were analysed by automated thermal desorption gas 163 
chromatography/mass spectrometry.  A Perkin Elmer system was used for analysis combining a 164 
TurboMass MS 4.1 Autosystem XL GC and Automatic Thermal Desorption system (ATD 400 165 
PerkinElmer, Wellesley MA).  The gas carrier was CP-grade helium (BOC gases Guildford UK) passed 166 
through a combined trap for removal of hydrocarbons, oxygen and water vapour.  A wall-coated Zebron 167 
ZB624 chromatographic column was used with dimensions 60 x .04 x 0.25mm (internal diameter), the 168 
liquid phase comprising a 0.25 µm layer of 6% cyanopropylphenyl and 94% methylpolysiloxane. 169 
 170 
Thermal desorption tubes were initially purged for 2 minutes to remove air and water vapour and then 171 
desorbed for 5 minutes at 300°C. The automatic thermal desorption valve temperature was set at 180°C 172 
and TD tubes were desorbed onto the secondary cold trap, which was initially maintained at 30°C.  Once 173 
desorption was complete, the secondary trap was heated to 320°C using the fastest available heating rate 174 
and then maintained for 5 minutes. The effluent was transferred to the gas chromatograph through a 175 
transfer line heated to 210°C.  The gas chromatograph oven was maintained at 50°C for 4 minutes after 176 
injection and then raised at a rate of 10°C/min to 220°C and then held for 9 minutes.  Eluted products 177 
were transferred to the mass spectrometer via a line heated to 240°C. Electron ionisation (70eV) was 178 
used.  Full scan mode was selected with mass-to-charge ratios from 33 to 350 m/z with a scan time of 0.3 179 
second and 0.1 second interscan delay to produce a total ion count (TIC) chromatogram. 180 
Study 2  181 
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Samples were transferred to the laboratory packed in dry ice inside insulated containers and on arrival 182 
were stored at -80°C until analysis.   183 
Aliquots (5ml) of the defrosted samples were placed in gas sampling bags which were then sealed and 184 
filled with hydrocarbon-free air and incubated for 10 minutes at body temperature. A portable air pump 185 
was then used to draw 500ml of headspace through  TD tubes packed with 50% Carbotrap and 50% 186 
Tenax. Full details have been published elsewhere 16 187 
 188 
Data and statistical analysis 189 
 Study 1 190 
Compound identification was achieved using Automated Mass Spectral Deconvolution and Identification 191 
(AMDIS version 2.62) software and the National Institute of Standards and Technology mass spectral 192 
library.  Quantification was achieved by comparing the area of each compound peak with the peak area 193 
associated with the known amount of d8 toluene. 194 
 195 
Concentration data proved to be heavily right-skewed, therefore a non-parametric approach was adopted. 196 
A McNemar test was used to determine whether the probability of a compound to be present before or 197 
after the diet was significant.  When present a Wilcoxon Rank Test was used to see if the compound was 198 
present in different quantities. Raw TIC data (i.e. a matrix of time vs. ion abundance) were also subjected 199 
to Principal Components Analysis (PCA)27 using Matlab (version 6/5 Mathworks Inc USA incorporating 200 
functions from the PLS Toolbox version 2.0 Eigenvector Research Inc USA). 201 
Study 2  202 
Compound identification and quantification were carried out as for study 1. In any given faecal headspace 203 
sample, automated mass spectral deconvolution and identification (AMDIS) would identify between 100-204 
300 different compounds and it was therefore found necessary to select a subset of those we observed to 205 
render statistical analysis tractable.  Three approaches were followed to provide a list of what we have 206 
termed ‘candidate compounds’.  The list comprised first compounds that appeared to be most abundant 207 
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from inspection of the results obtained using AMDIS; second compounds that appeared to discriminate 208 
between patient groups by visual inspection of a subset of pre treatment sample chromatograms and third 209 
compound selected on the basis of a search of the relevant literature. An initial generic list was made 210 
including short-chain fatty acids (SCFAs) and their derivatives, phenolic compounds and indoles and 211 
sulfides.  This list was then refined according to publications dealing more explicitly with VOC profiles 212 
in disease.  A final list of compounds was obtained in this way. 213 
 214 
Results  215 
Study 1  216 
 217 
Of the 12 volunteers recruited, two females withdrew before the feeding commenced.  During the first 218 
feeding period 2 withdrew after 2 days feeding, one (female having E028) because of persistent hunger 219 
and the other (male having Modulen-IBD) because of insomnia attributed to an empty stomach.  Eight 220 
subjects completed the first phase.  A further subject (male Modulen-IBD) withdrew after 4 days in the 221 
second phase because of malaise and headaches.   222 
 223 
Stool consistency and frequency showed no change.  There was a consistent change in stool colour from 224 
browns towards green on E028 extra (r=0.639, p<0.05 Spearman test), and a similar but less marked 225 
effect was seen after Modulen-IBD (r=0.598, p<0.05).  Faecal colour had returned to normal by the start 226 
of the second feeding period. 227 
 228 
All subjects showed deterioration in odour on E028 extra and 5 out of 6 on Modulen-IBD.  One volunteer 229 
did not record his breath changes on a daily basis. A Spearman test showed a significant difference 230 
between the odour of the breaths of the volunteers before they started and the last day of the diet (E028 231 
extra r=0.575 p<0.05, Modulen-IBD r=0.574 p<0.05). Subjects breath odour had returned to normal at the 232 
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start of the second feeding period. Numerical results are presented as mean with upper and lower 233 
quartiles. The frequency distributions for all compounds were found to be highly skewed with a 234 
proportion of nondetects; therefore, a nonparametric statistical approach was adopted. 235 
 236 
Over 140 compounds were seen in the breath analysis including aldehydes, ketones, saturated and non-237 
saturated hydrocarbons, organic acids, alkenes, alcohols and furans.  The compounds also varied between 238 
volunteers. As at least one third of compounds were known to be environmental contaminants, e.g. 239 
benzene, toluene, xylene, we concentrated on two marker compounds known to be bacterial metabolites, 240 
phenol and indole. 241 
The mean alveolar gradient for indole on a normal diet was 0.034 ±  SD 0.029.  There is little change 242 
following  Modulen-IBD  0.041 ±  SD 0.028 (NS).  After E028 it rose to 0.149 ±  SD 0.099 (NS)  The 243 
differences between the values after diet did not differ significantly from those before, but the aveolar 244 
gradient after E028 was significantly higher than that after Modulen-IBD (P<0.03). 245 
The mean level of alveolar gradient for phenol on the breath on a normal diet was 0.024 ± SD 0.017.  246 
After Modulen-IBD it rose to 0.055 ±  SD 0.025 (NS).  After E028 the levels were 0.229 ±  SD 0.152 247 
(p<0.05).  The increase after E028 was significantly greater to that after Modulen-IBD P=0.035  After 3 248 
weeks of normal eating, breath chemicals had in every case returned to levels indistinguishable from 249 
those present at the start of the first period of enteral feeding. 250 
 251 
Results 252 
Study 2:  253 
 254 
At the start of treatment all 17 patients had active disease as confirmed by a Harvey and Bradshaw index 255 
of >6 and raised concentration of C-reactive protein (CRP) in the blood. 9 patients were receiving no 256 
medication, 4 were taking 5ASA compounds, 2 were taking 5ASA with Azathioprine, 1 taking 257 
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Azathioprine alone and 1 taking Azathioprine and Prednisolone. Patients were asked to continue the same 258 
medication throughout the study and this was not changed in any way, remission being achieved in all 259 
cases by the addition of enteral feed.  The mean Harvey & Bradshaw (H&B) before treatment was 6.88 ±  260 
SD 2.93 falling to 4 ± SD 5.50 after treatment, (p<0.05).  The initial mean CRP was 36.0 ±  SD 41.3mg/L 261 
falling to 8.11 ±  SD 3.59 after treatment (p<0.05).  262 
 263 
The results of GC/MS faecal analysis are summarised in Table 1. Many compounds of known bacterial 264 
origin were present in the initial sample.  These included propanoic and butanoic acids, para-cresol, 265 
indole, dimethyl disulphide and phenol.  The concentrations of the SCFAs fell dramatically after enteral 266 
feeding.  No difference was discerned in the fall of concentrations of bacterial metabolites in those 267 
subjects receiving enteral feeds alone, and those who continued their previous medication. Thus the 268 
results of all the patients were analysed together.  269 
 270 
There were also however, a number of potentially toxic compounds present.  These included the alcohols, 271 
1-propanol and 1-butanol as well as the methyl and ethyl esters of propanoic acid and butanoic acid.  272 
After treatment, the amounts of these compounds also fell significantly.   The SCFA-esters disappeared 273 
virtually completely and there was a significant fall in the concentration of 1-propanol and 1-butanol.  274 
However, other chemicals including those derived by bacterial breakdown of amino acids, phenol and 275 
indole did not change significantly (table 1).   276 
 277 
Discussion 278 
 279 
The present study demonstrates changes in chemicals of microbial origin in both healthy controls and in 280 
patients with CD after administration of enteral feeds.  Our first study confirms reports of stool colour  281 
change during treatment with the development of breath odour. It is probable that this was the result of 282 
the cessation of the normal microbial breakdown of biliverdin (green) to stercobilin (brown).  283 
13.1.16 vs10  pg. 12 
 284 
We also attempted to assess bacterial activity by determination on the breath of known bacterial 285 
metabolites that might be absorbed into the blood stream from the colon.  Many chemicals are present in 286 
breath and urine and we detected 140. Their origins of many are poorly understood.  We therefore 287 
concentrated on changes in the excretion of two chemicals whose synthesis by the microbiota is well 288 
understood, namely phenol and indole.14,15 289 
 290 
Phenol and indole are produced by the microbial conversion of tyrosine and tryptophan respectively .  291 
Much less is produced when carbohydrate fermentation is continuing in the colon..  Conversely, when 292 
carbohydrate was withdrawn from the diet, phenol production from endogenous protein sources such as 293 
intestinal secretions and exfoliated cells was increased 17,18   294 
 295 
 In the present study, phenol and indole identified on the breath showed a significant increase in 296 
concentration after feeding with Modulen-IBD and an even greater increase after E028extra, which 297 
rapidly returned to base line on resumption of a normal diet.    This is consistent with a switch in colonic 298 
fermentation to a protein-based pattern, as an effect of ingesting carbohydrate in the form of 299 
maltodextrins - simple sugars that are absorbed high in the small intestine - rather than complex 300 
carbohydrates that may pass down to be fermented by the colonic flora. Indole is malodorous and may 301 
contribute to the unpleasant breath odour reported by our volunteers.    302 
 303 
The term ‘enterometabolic disease’ has been suggested for non-infective conditions arising from 304 
abnormal fermentation by the colonic microbiota 13. Patients with IBS have a similar abnormal gut flora 305 
to that seen in CD.11,20,23 and have a markedly increased excretion of a bacterial product, hydrogen. This 306 
was dramatically reduced, with highly significant reduction in symptoms, when patients were switched 307 
from a standard diet to an exclusion diet, suggesting that the diet reduced microbial activity 24.  Support 308 
for this concept was provided by the demonstration of reduced hydrogen excretion in patients with IBS , 309 
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again with significant improvement in symptoms, when microbial activity was reduced  by administration 310 
of antibiotics or by enteral feeding .25 311 
Is seems possible that CD like IBS may be an ‘entero-metabolic disorder’, 13  and that enteral feeding  is 312 
effective because it reduces the metabolic activity of an abnormal colonic flora? 313 
 314 
There is strong evidence that the host microflora provokes an immunological response in CD.  Duchmann 315 
and his colleagues showed that monocytes from the peripheral blood and the lamina propria were 316 
activated when incubated with preparations of faecal bacteria from other subjects, but not by such 317 
preparations derived from the faeces of the host.  Monocyte activation occurred only when host faeces 318 
was incubated with cells obtained from the lamina propria from sites of active CD. No activation was 319 
seen in monocytes obtained from areas where no active CD was present, suggesting that monocytes in 320 
areas of active CD were specifically targeted against the host microflora.10 321 
 322 
This finding has been supported by later studies that demonstrated that the great majority of 323 
microrganisms found in the faeces of patients with IBD were coated with immunoglobulin, including 324 
IgA, IgG and IgM, whereas in normal subjects or those with IBS, less than 20% were so affected 12.   325 
Furthermore, a significant reduction in the number of microorganisms coated with immunoglobulin was 326 
seen after 2 weeks treatment with corticosteroids in UC, and a similar response occurred in CD after a 327 
two week course of elemental feeding.  This suggested that the immune response to the flora had been 328 
significantly reduced, an interpretation supported by the finding that patients with CD and UC in long 329 
term remission had similar numbers of coated bacteria to those seen in healthy controls.12    330 
No specific pathogen has as yet been confirmed as being the cause of CD, but it has been demonstrated 331 
that the faecal flora is abnormal with an overgrowth of facultative anaerobes and reduction in the numbers 332 
of important beneficial species such as Lactobacilli and Bifidobacter.11,20    Although previous studies of 333 
the effects of enteral feeding on the composition of the bacterial flora in CD, had been inconclusive,21,22    334 
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a recent study of the entire gut mucosal microbiome in a child with CD before and after nutritional 335 
therapy showed that the flora, initially markedly abnormal, returned after therapy, to a pattern very 336 
similar to that found in a healthy control 26.  Likewise, it has also been shown that enteral nutrition in CD 337 
may reduce the levels of certain bacteria within the Firmicutes.  These bacteria are important producers of 338 
SCFAs and this report is in keeping with our discovery of reduced SCFA production. 27   339 
 340 
Unfortunately, it was not possible in the present study to perform complex studies of changes in the gut 341 
microbiome, but changes in bacterial metabolites serve as valuable markers of its metabolic activity. 342 
SCFAs have an important function in the colon especially butanoic acid which is a major source of 343 
nutrition for colonocytes.19  They are produced by the microbial fermentation of undigested complex 344 
carbohydrates entering the caecum and the fall in faecal SCFA concentration found after enteral feeding 345 
in our patients with CD was consistent with reduction in colonic fermentation.   346 
 347 
Such a reduction in fermentation might be beneficial if it resulted in less production of toxic metabolites.  348 
There were highly significant falls in the concentrations of number of chemicals including 1-propanol, p-349 
cresol, phenol, 1-butanol, dimethyl disulphide and fatty acid ethyl esters  (Table 1).  These are known to 350 
be toxic chemicals which we have shown not to be present in the stools of healthy volunteers. 16   It seems 351 
possible that the production of such chemicals might be a factor initiating an immune attack on the 352 
microflora.   This could lead to coating of microflora with immunoglobulin – a suggestion which has been 353 
supported by the significant reduction in bacterial coating seen after 2 weeks feeding with enteral 354 
feeds.12,16 355 
 356 
Similar toxic chemicals also appear in UC, but in contrast to CD, do not fall after enteral feeding, but 357 
only after successful treatment by immunosuppression with prednisolone16. Although evidence on the role 358 
of diet in UC remains weak, this suggests that the microflora in UC differs from that in CD in that it 359 
derives its nutritional requirements, not from food residues, but from other substances present in the large 360 
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intestine – possibly mucus or intestinal secretions.   It is therefore feasible, that the production of toxic 361 
chemicals resulting from abnormal bacterial metabolism, may be an important factor in the initiation of 362 
an immune attack on the microflora in inflammatory bowel disease. 363 
 364 
 365 
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 465 
Table 1 Changes in faecal chemicals before and after elemental feeding in patients with CD. 466 
 467 
 VOC concentration (ng/l) 
Median (lower quartile, upper quartile) 
Compound Pre-
treatment 
Post-
treatment 
p-value 
acetone 
57 
(38, 128) 
80 
(50, 104) 
0.435 
propanoic acid 
169 
(0, 328) 
12 
(0, 84) 
0.031* 
butanoic acid 
1110 
(316, 
1596)) 
24 
(0, 104) 
0.001* 
1-propanol 
229 
(41, 892) 
36 
(0, 233) 
0.025* 
propanoic acid, ethyl 
ester 
19 
(0, 117) 
0 
(0, 15) 
0.008* 
butanoic acid, methyl 
ester 
19 
(7, 121) 
0 
(0, 1) 
0.013* 
butanoic acid, ethyl 
ester 
46 
(4, 255) 
0 
(0, 15) 
0.008* 
p-cresol 
518 
(118, 
1160) 
480 
(144, 
1051) 
0.687 
indole 
118 
(54, 146) 
20 
(0, 128) 
0.125 
dimethyl disulphide 
83 
(34, 683) 
39 
(0, 140) 
0.113 
1-butanol 
99 
(57, 256) 
58 
(0, 199) 
0.030* 
butanoic acid, 3-methyl 
147 
(48, 504) 
0 
(0, 45) 
0.015* 
phenol 
64 
(16, 102) 
24 
(10, 177) 
0.332 
 
Concentrations of volatile organic compounds (VOCs) in fecal headspace from 
healthy controls and volunteers diagnosed with Crohn’s disease (CD) before and after 
treatment. Median and upper and lower quartile values are shown. Differences were 
examined by Wilcoxon matched pairs test, p<0.05 (two-sided) being considered 
significant and indicated by an asterisk. 
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 471 
Copy of the stool colour chart provided to volunteers in study 1. The colours are numbered from brown 472 
(1) to increasing greenness (5) the blue is just for the slide background.  This is not for publication but to 473 
be made available for any readers who may enquire about it.   474 
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